Form 4: Core Scientific Legal Officer Sells 50,000 Shares Under Pre-Arranged Plan

Core Scientific's Chief Legal and Administrative Officer, Todd M. DuChene, sold 50,000 shares of common stock on May 27, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Todd M. DuChene, Chief Legal and Administrative Officer of Core Scientific, Inc. (CORZ), reported the sale of 50,000 shares of common stock.
• The transaction occurred on May 27, 2025, at a weighted average price of $11.2317 per share.
• The shares were sold in multiple transactions within a price range of $11.2084 to $11.2578.
• Following this transaction, Mr. DuChene beneficially owns 2,160,102 shares of Core Scientific common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, indicating a pre-scheduled transaction.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the fact that it's under a Rule 10b5-1 plan mitigates the negative implications, suggesting a pre-planned diversification or liquidity event rather than a reaction to adverse non-public information.

Positives

• The transaction was executed under a Rule 10b5-1 plan, which suggests the sale was pre-scheduled and not based on new, non-public information, mitigating potential negative interpretations of insider selling.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence in the company's near-term prospects, although this is less pronounced with pre-arranged plans.

Risks

• While the sale was pre-planned, significant insider selling over time could potentially signal a lack of confidence from management, which might be a risk for investor sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The filing indicates that Todd M. DuChene holds the title of Chief Legal and Administrative Officer.

Industry Context

This Form 4 filing is specific to an insider transaction at Core Scientific and does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: May observe the insider sale, but the 10b5-1 plan context suggests it's a routine, pre-planned transaction rather than a signal of management's immediate view on company performance.

Key Dates

Recommendation

Keywords

Core Scientific, CORZ, Form 4, insider trading, stock sale, Todd DuChene, beneficial ownership, Rule 10b5-1, Chief Legal and Administrative Officer